Biosergen publishes interim report for first half of 2026
Biosergen AB has released its interim report for the first half of 2026. The report details significant changes within the company and progress in its clinical development.
Biosergen AB has published its interim report for the first half of 2026, which is available on the company's website. The report covers a period marked by substantial developments within the organization.
During the first half of the year, Biosergen focused on advancing its BSG005 drug candidate towards the next stage of clinical development. Concurrently, the company worked on strengthening the manufacturing and regulatory foundations necessary for the program.
The report also highlights a planned merger with Flerie. This merger is intended to secure Biosergen's funding and support its ongoing drug development initiatives. The company anticipates that this strategic move will bolster its position and provide necessary resources for future research.
Biosergen expects the merger to facilitate the continuation and potential acceleration of its pipeline development.